Product Description
AN-1792 was the first active immunotherapy strategy forÊAlzheimer's disease. AN-1792 consists of synthetic full-length A_Êpeptide with QS-21 adjuvant. The rationale was that AN-1792 would induce an immune response that would remove brain amyloid deposition. (Sourced from: https://www.alzforum.org/therapeutics/an-1792)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: Eastern America
Company Founding Year: 1886
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|